Nat Commun:科学家开发“超级”多肽将药物送达脑损伤部位

2016-06-30 生物谷 生物谷

来自美国Sanford Burnham Prebys Medical Discovery Institute的科学家们最近发表了一项最新研究进展,他们开发了一种用于创伤性脑损伤治疗的新技术。相关研究结果发表在国际学术期刊Nature Communication上,该研究为将药物送达脑部损伤部位提供了一种新方法。在美国每年有大约250万人因车祸,坠落或暴力因素遭受创伤性脑损伤。目前对于急性脑损伤的干

来自美国Sanford Burnham Prebys Medical Discovery Institute的科学家们最近发表了一项最新研究进展,他们开发了一种用于创伤性脑损伤治疗的新技术。相关研究结果发表在国际学术期刊Nature Communication上,该研究为将药物送达脑部损伤部位提供了一种新方法。

在美国每年有大约250万人因车祸,坠落或暴力因素遭受创伤性脑损伤。目前对于急性脑损伤的干预方法主要通过降低颅内压维持血流,但是至今没有得到批准的药物能够阻止引起二次损伤的级联事件的发生。

现在处于临床前试验阶段用于减轻初始损伤后二次脑损伤的小分子化合物有一百多种,这些候选药物能够阻断炎症,高水平自由基,神经元过度兴奋以及细胞凋亡信号等引起二次损伤的事件的发生。

文章作者表示:“我们的目标是找到能够代替直接脑部药物注射的新方法,直接注射具有侵入性经常会导致并发症的发生。我们开发了一种多肽能够进行药物运输,这就意味着通过静脉注射给药仍然可以有足够的药物到达损伤位置发挥治疗作用。”

他们开发的这种CAQK多肽能够与脑细胞周围的硫酸软骨素蛋白聚糖结合,这些糖修饰蛋白的含量会在脑损伤之后出现增加。研究人员证明他们不仅可以通过CAQK将药物尺寸的分子以及纳米颗粒送达急性脑损伤小鼠模型的损伤区域,他们还检测了该多肽与发生损伤的人类脑组织样本的结合能力,结果表明仍然具有相同的特异性。

除此之外通过将这种多肽与一些成像仪器能够检测到的成像材料结合在一起还可以开发鉴定脑损伤的新工具。由于该多肽能够运输装载着生物大分子的纳米颗粒,因此还可以用于生物酶或者基因沉默治疗方法。

目前该研究团队正在动物模型上进行该技术的进一步验证。


原始出处:

Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She ZG, Kotamraju VR, Ranscht B, Krajewski S, Teesalu T, Bhatia S, Sailor MJ, Ruoslahti E.A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acutebrain injuries.Nat Commun. 2016 Jun 28;7:11980. doi: 10.1038/ncomms11980.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086873, encodeId=a8a420868e34d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 23 04:44:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881142, encodeId=f961188114291, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 22 05:44:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397028, encodeId=12c3139e028c4, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530035, encodeId=af0f1530035a0, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-08-23 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086873, encodeId=a8a420868e34d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 23 04:44:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881142, encodeId=f961188114291, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 22 05:44:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397028, encodeId=12c3139e028c4, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530035, encodeId=af0f1530035a0, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-11-22 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086873, encodeId=a8a420868e34d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 23 04:44:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881142, encodeId=f961188114291, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 22 05:44:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397028, encodeId=12c3139e028c4, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530035, encodeId=af0f1530035a0, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086873, encodeId=a8a420868e34d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Aug 23 04:44:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881142, encodeId=f961188114291, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 22 05:44:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397028, encodeId=12c3139e028c4, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530035, encodeId=af0f1530035a0, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Sat Jul 02 09:44:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-07-02 fusion

相关资讯

ACS 2015:新型多肽探针有助于检测全身血栓部位

本周早些时候在波士顿开展的ACS会议上,马萨诸塞州总医院(MGH)的研究人员展示出他们新研发出的探针,这种新型探针可提高检测患者机体血栓的速度,成功在小鼠身上验证并将于今年年底应用于人体试验。众所周知,机体若出现血栓则非常危险,甚至会致命。所以,越早清除血栓,它能引起机体出现心脏病、中风或其他致命性疾病的风险就越小。若一个人因机体血栓的出现而导致中风,则其再次患中风的风险增加,但是因为血栓位置不同

Nature子刊:让多肽带你深入肿瘤

肿瘤细胞比较容易摄取带有生化小分子的多肽。科学家们正在利用这一点,开发新的癌症治疗方式。 深入肿瘤 长期以来科学家们一直在努力理解和治疗癌症,尽管癌症生存率正在逐渐提升,但人们并没有找到完美的治疗方式。人们面临的挑战是,要让癌症药物到达最需要治疗的区域,并有效进入细胞。血液中的药物往往只能到达肿瘤的部分区域。这是因为肿瘤的内压较高,液体更倾向于流出,导致血液中的药物难以扩散进去。此

鹰嘴豆可提取抗肿瘤蛋白质和多肽

        记者近日从中科院新疆理化技术研究所获悉,该所资源化学研究室的科研人员研制出一种从鹰嘴豆豆瓣中提取天然抗肿瘤活性蛋白质和多肽的方法。相关研究成果日前获国家发明专利授权。   目前,肿瘤已成为仅次于心脑血管疾病的第二大杀手,寻找高效、低毒的抗肿瘤药物成为世界范围内相关研究的热点之一。生物活性肽是一类天然存在于动、植物和微生物等生物体内的多功能化合物。动、植物蛋白质经过蛋白酶解以及

Nat Commun :一种新型多肽C99能遏制阿尔茨海默氏症发病

日本同志社大学的一个研究小组宣布,他们开发出一种新物质,能遏制导致阿尔茨海默氏症(早老性痴呆)的β淀粉样蛋白的生成。这一成果将有助于开发出副作用很小的预防和治疗阿尔茨海默氏症的方法。【原文下载】 同志社大学副教授舟本聪率领的研究小组发现,一种酶与一种称为“C99”的蛋白质结合之后形成β淀粉样蛋白。如果遏制这种酶发挥作用,就有可能对阿尔茨海默氏症进行治疗。但是,由于这种